FTSE MIB
33.786,07 +39,41 (+0,12%) Dow Jones
37.930,69 +27,40 (+0,07%) Nasdaq
15.620,73 +15,25 (+0,10%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
78,92 -0,08 (-0,10%) Bitcoin EUR
54.861,66 +1.136,39 (+2,12%)
TG Therapeutics, Inc. (TGTX)
| Chiusura precedente | 15,88 |
| Aperto | 16,27 |
| Denaro | 15,59 x 2000 |
| Lettera | 15,69 x 600 |
| Min-Max giorno | 15,56 - 16,76 |
| Intervallo di 52 settimane | 6,46 - 35,67 |
| Volume | |
| Media Volume | 3.730.036 |
| Capitalizzazione | 2,417B |
| Beta (5 anni mensile) | 2,32 |
| Rapporto PE (ttm) | 173,78 |
| EPS (ttm) | 0,09 |
| Prossima data utili | 30 lug 2024 - 05 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 31,57 |
GlobeNewswireTG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held in Milan, Italy. A link to the presentation is included below. Michael S. Weiss, Chairman and Chief Executive Officer of
- GlobeNewswire
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held October 11 – 13, 2023, in Milan, Italy. Abstr
- GlobeNewswire
TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
Fireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ETNEW YORK, Sept. 22, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 2023 Cantor Global Healthcare Conference, being held at the Intercontinental Barclay Hotel, in New York City on September 26 - 28, 2023. The fireside chat is scheduled to take place on Tuesday, September 26, 2023, at 12:25 PM ET. A
